Funding and Investments

The CGT market is evolving rapidly, with billions in investments and thousands of strategic deals shaping its trajectory. Companies that understand the landscape and anticipate future deal trends will have the competitive edge needed to thrive. Whether you are a biotech executive, investor, R&D leader, or regulatory strategist, this report provides data-driven insights to inform…

Kalorama Information’s Cell and Gene Therapy Deals Analysis: Financings, Partnering, M&A, Tech Transfers, IPOs/SPACs, Other Deals, 2021-2024 offers a comprehensive look at the dynamic and rapidly evolving cell and gene therapy market. This report highlights the significant deal-making activities that have taken place from Q1 2021 to Q1 2024, providing valuable insights for companies and…

Explore the dynamic world of cell and gene therapy deal-making with Kalorama Information’s comprehensive report, Cell and Gene Therapy Funding and Deals Analysis: Financings, Partnering, M&A, Tech Transfers, IPOs/SPACs, Other Deals, 2021-2023. This report tracks the deal-making activities in cell and gene therapy since 2021, providing insightful graphs of quarterly trends from 2021-2023 and detailing…

The cell and gene therapy (CGT) sector has experienced remarkable growth, with funding reaching $70 billion in 2021. As barriers to entry lower and the number of approved therapies with proven track records increases, over a thousand companies have entered or expanded within this dynamic field. Keeping up with this rapidly evolving industry is essential,…

In vitro diagnostic (IVD) products continue to experience robust sales growth across various categories, driven by new product innovations, global health spending shifts, regulatory changes, and evolving disease trends. In this dynamic market, companies are strategically acquiring new assets to enhance their revenue streams and foster product innovation. Kalorama Information’s latest report, Mergers and Acquisitions…